FDA Issues Update on Adverse Event Reports Related to Essure
Although Bayer stopped selling its Essure permanent birth control device mid-2018, FDA has continued to monitor product safety via postmarket surveillance study data.
FDA recently announced the publication of Bayer’s second quarterly analysis report of adverse events for September 2020 through the end of November 2020. According to FDA, these events are from social media posts and may be connected to litigation, but they are not necessarily new adverse events.
“Reports do not necessarily represent unique cases, but rather events identified in comment threads from social media posts, sometimes by the same individual. The most common patient problems reported were pain, perforation, foreign body/device fragment in patient, pregnancy (including ectopic), heavier periods (menses/hemorrhage), and hypersensitivity. The majority of reports (94%) are related to potential device removal, which is consistent with the MDRs for Essure since 2017. For the 9 death reports, the social media posting dates (when provided) ranged from the year 2013 to 2015. None of the death reports provided a date for the reported death event… The limited information prevents the ability to draw any conclusions as to whether the device, or its removal, caused or contributed to any of the reported deaths or other events in the reports.” – FDA, “Problems Reported With Essure“
Related Articles
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
-
The updated guidance document clarifies what constitutes a statement of the basis for the deficiency and includes examples of well-constructed deficiencies and industry responses to facilitate a more efficient review process.
